High-level results of KOMET, the largest, global randomised double-blind placebo-controlled multicentre Phase III trial in adults with neurofibromatosis type 1 who have symptomatic, inoperable ...
(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Thursday that the US Food and Drug Administration has approved Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib) for the ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Koselugo’s approval was based on data from the phase 3 ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ: AZN)Koselugo (selumetinib) for adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, ...
The FDA has approved selumetinib (Koselugo, AstraZeneca) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Selumetinib, an oral kinase ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. An oral therapeutic significantly reduced the number of ...
Alexion, AstraZeneca Rare Disease, will deliver 20 presentations, including five oral presentations across generalised myasthenia gravis (gMG), neurofibromatosis type 1 (NF1) plexiform neurofibromas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results